Oracle shares surged as the tech giant unveiled plans to raise up to $50 billion this year, fueling an aggressive expansion of its AI and cloud infrastructure to meet soaring demand from clients like Nvidia and OpenAI.
IDEAYA Biosciences shares have retreated from recent highs, sparking debate among investors. While a discounted cash flow model suggests deep undervaluation, price-to-sales metrics paint a contrasting picture of a premium stock. We examine the numbers behind the volatility and what it signals for the precision oncology company's future.
Fresh financial data from QuidelOrtho reveals ongoing challenges, including constant currency revenue declines and pressured cash flow, forcing investors to weigh the stock's risk-reward profile as its momentum appears to fade.
While Wall Street chases the latest weight-loss drug headlines, Novo Nordisk's recent launch of an oral GLP-1 therapy and its entrenched insulin business present a compelling value proposition for long-term investors.
French pharmaceutical giant Sanofi has discontinued development of its experimental mRNA flu vaccine, citing a strategic reprioritization. The decision comes as influenza activity remains high across much of the United States, with significant hospitalizations and deaths reported this season.
Novo Nordisk's experimental combination therapy CagriSema has demonstrated superior blood sugar control and weight loss compared to its own blockbuster Wegovy in a major Phase 3 trial. However, the emerging data suggests it may still trail behind Eli Lilly's rival drug Zepbound in key efficacy measures, setting the stage for a fierce market battle.
Shares of Aviat Networks (NASDAQ: AVNW) have seen notable volatility, recently trading around $21.81. Analysis suggests the stock may be undervalued relative to industry peers, with strong future earnings growth projected. We examine whether this small-cap network specialist presents a timely opportunity for investors.
Investment firm Monument Capital Management has completely exited its position in Grand Canyon Education, selling 19,133 shares. The move comes as the education services provider navigates legal challenges and market underperformance.
Amidst market volatility, Roper Technologies emerges as a notable oversold candidate. The diversified tech conglomerate, boasting a 33-year dividend growth streak, shows signs of a potential reversal while strategically integrating AI across its vertical software portfolio.
Navitas Semiconductor is strategically shifting its focus from volatile consumer electronics to the high-growth, high-margin arenas of AI data centers and electric vehicles, underscored by a pivotal partnership with industry giant Nvidia.
NVIDIA has significantly revised its once-floated $100 billion investment plan for OpenAI, opting for a more measured commitment. The strategic shift underscores the chipmaker's focus on business discipline and diversifying its partnerships across the booming AI ecosystem, even as it remains central to OpenAI's operations.
While Medicare provides a crucial safety net at 65, significant gaps in coverage for dental, vision, and long-term care can lead to six-figure annual expenses. Proactive planning with HSAs, specialized insurance, and strategic budgeting is essential to protect retirement savings.
While 3M shares have significantly underperformed the broader market and its industrial peers over the past year, Wall Street maintains a cautiously optimistic stance, betting on the diversified giant's long-term recovery and earnings resilience.
Spanish healthtech startup Biorce has closed a substantial Series A round, backed by prominent venture capital and angel investors, to scale its AI-driven clinical trial solution, Aika, internationally amid a tightening regulatory landscape.
The FDA has issued a complete response letter for Aquestive Therapeutics' sublingual epinephrine film Anaphylm, citing concerns over packaging and user instructions. The company aims to address the issues and resubmit its application by the third quarter of this year.
As major indices climb, investors are sifting through economic crosscurrents to find resilient tech innovators. We examine three companies—Veracyte, monday.com, and Zeta Global—whose strategic moves and financial momentum position them for potential growth.
NAPCO Security Technologies (NSSC) reported strong fiscal second-quarter results, with record revenue and expanding profitability. The company highlighted the sustained momentum of its high-margin recurring service model and announced a dividend increase.
IDEXX Laboratories (IDXX) reported robust double-digit growth for Q4 2025, driven by record placements of its premium diagnostic instruments and expanding test utilization. While acknowledging persistent softness in U.S. veterinary visit volumes, the company outlined a confident initial 2026 forecast, banking on its innovation pipeline and the transformative impact of its inVue Dx system.
As the United States approaches its 250th anniversary, USA TODAY examines the enduring legacy of the companies that shaped the nation's culture, economy, and global identity.
Amid tightening climate regulations, Southern States LLC launches a new line of high-voltage switching products that replace the potent greenhouse gas SF6 with a readily available blend of carbon dioxide and oxygen, promising a dramatic reduction in environmental impact without compromising grid reliability.
